• Consensus Rating: Hold
  • Consensus Price Target: $158.14
  • Forecasted Upside: 45.74%
  • Number of Analysts: 21
  • Breakdown:
  • 2 Sell Ratings
  • 11 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$108.51
▼ -4.08 (-3.62%)

This chart shows the closing price for ILMN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Illumina Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ILMN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ILMN

Analyst Price Target is $158.14
▲ +45.74% Upside Potential
This price target is based on 21 analysts offering 12 month price targets for Illumina in the last 3 months. The average price target is $158.14, with a high forecast of $253.00 and a low forecast of $100.00. The average price target represents a 45.74% upside from the last price of $108.51.

This chart shows the closing price for ILMN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 21 investment analysts is to hold stock in Illumina. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 2 sell ratings
12/20/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 2 sell ratings
3/20/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 2 sell ratings
6/18/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 2 sell ratings
9/16/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 2 sell ratings
12/15/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 2 sell ratings
3/14/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 2 sell ratings
5/13/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 2 sell ratings
6/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/11/2024Evercore ISILower TargetOutperform ➝ Outperform$195.00 ➝ $175.00Low
6/6/2024TD CowenLower TargetHold ➝ Hold$140.00 ➝ $122.00Low
6/3/2024Jefferies Financial GroupInitiated CoverageHold$115.00Low
5/7/2024StephensReiterated RatingOverweight ➝ Overweight$170.00Low
5/6/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$185.00 ➝ $176.00Low
5/3/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$125.00 ➝ $128.00Low
4/10/2024BarclaysBoost TargetUnderweight ➝ Underweight$85.00 ➝ $100.00Low
4/10/2024StephensReiterated RatingOverweight ➝ Overweight$170.00Low
4/9/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$253.00Low
3/20/2024OTR GlobalReiterated RatingPositive ➝ MixedLow
2/14/2024StephensReiterated RatingOverweight ➝ Overweight$170.00Low
2/9/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$258.00Low
1/25/2024BarclaysBoost TargetUnderweight ➝ Underweight$50.00 ➝ $80.00Low
1/16/2024HSBCDowngradeBuy ➝ HoldLow
1/4/2024TD CowenDowngradeOutperform ➝ Market Perform$144.00Low
12/19/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$260.00 ➝ $258.00Low
12/18/2023ScotiabankUpgradeSector Perform ➝ Sector Outperform$185.00Low
12/15/2023Sanford C. BernsteinUpgradeUnderperform ➝ Market PerformLow
12/14/2023StephensInitiated CoverageOverweight$170.00Low
12/14/2023GuggenheimInitiated CoverageBuy$155.00Low
12/13/2023Wolfe ResearchInitiated CoverageOutperform$175.00Low
12/12/2023Bank of AmericaDowngradeNeutral ➝ Underperform$140.00 ➝ $100.00Low
12/11/2023CitigroupUpgradeSell ➝ Neutral$85.00 ➝ $120.00Low
11/13/2023Piper SandlerLower TargetOverweight ➝ Overweight$200.00 ➝ $190.00Low
11/10/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$210.00 ➝ $120.00Low
11/10/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$210.00 ➝ $120.00Low
10/16/2023Piper SandlerLower TargetOverweight ➝ Overweight$275.00 ➝ $200.00Low
10/12/2023Stifel NicolausReiterated RatingBuy ➝ Buy$200.00Low
9/29/2023Stifel NicolausLower TargetBuy ➝ Buy$225.00 ➝ $200.00Low
9/29/2023BarclaysLower TargetUnderweight ➝ Underweight$150.00 ➝ $100.00Low
9/29/2023HSBCLower Target$230.00 ➝ $171.00Low
9/28/2023Sanford C. BernsteinInitiated CoverageUnderperform$111.00Low
9/1/2023Evercore ISIReiterated RatingOutperform ➝ Outperform$240.00Low
8/16/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$300.00 ➝ $285.00Low
8/15/2023Piper SandlerLower TargetOverweight ➝ Overweight$290.00 ➝ $275.00Low
8/14/2023HSBCLower TargetBuy ➝ Buy$270.00 ➝ $235.00Low
8/10/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$235.00 ➝ $190.00Low
8/10/2023Evercore ISIBoost TargetOutperform ➝ Outperform$235.00 ➝ $240.00Low
8/10/2023Stifel NicolausLower TargetBuy ➝ Buy$265.00 ➝ $225.00N/A
8/10/2023Bank of AmericaLower Target$230.00 ➝ $210.00Low
8/10/2023CitigroupLower TargetSell ➝ Sell$180.00 ➝ $150.00Low
8/10/2023Credit Suisse GroupLower TargetNeutral ➝ Neutral$225.00 ➝ $200.00Low
8/10/2023Robert W. BairdLower Target$229.00 ➝ $180.00Low
8/8/2023UBS GroupLower TargetNeutral ➝ Neutral$240.00 ➝ $230.00Low
8/8/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$337.00 ➝ $328.00Low
4/26/2023Stifel NicolausBoost Target$235.00 ➝ $265.00Low
4/26/2023Robert W. BairdBoost Target$224.00 ➝ $229.00Low
4/14/2023Royal Bank of CanadaBoost TargetOutperform$300.00 ➝ $337.00Low
3/15/2023Royal Bank of CanadaLower TargetOutperform$303.00 ➝ $300.00Low
2/14/2023UBS GroupLower TargetNeutral$255.00 ➝ $240.00Low
2/8/2023Piper SandlerReiterated RatingOverweight$290.00Low
2/8/2023Stifel NicolausLower Target$285.00 ➝ $235.00Low
2/8/2023JPMorgan Chase & Co.Lower TargetNeutral$300.00 ➝ $271.00Low
2/8/2023Royal Bank of CanadaBoost TargetOutperform$284.00 ➝ $303.00Low
2/8/2023Bank of AmericaBoost Target$210.00 ➝ $230.00Low
2/8/2023SVB LeerinkBoost TargetOutperform$249.00 ➝ $250.00Low
2/8/2023BarclaysLower TargetUnderweight$160.00 ➝ $150.00Low
1/27/2023Piper SandlerLower Target$300.00 ➝ $290.00Low
1/25/2023ArgusDowngradeBuy ➝ HoldLow
1/17/2023Canaccord Genuity GroupLower TargetBuy$330.00 ➝ $300.00Low
1/10/2023Bank of AmericaLower Target$220.00 ➝ $210.00Low
1/10/2023CowenLower Target$350.00 ➝ $296.00Low
1/4/2023ScotiabankInitiated CoverageSector Perform$216.00Low
12/20/2022OTR GlobalUpgradeMixed ➝ PositiveLow
12/12/2022CitigroupDowngradeNeutral ➝ Sell$200.00 ➝ $180.00Low
12/6/2022Royal Bank of CanadaInitiated CoverageOutperform$282.00Low
11/14/2022Piper SandlerLower TargetOverweight$320.00 ➝ $300.00Low
11/7/2022Morgan StanleyLower TargetEqual Weight$240.00 ➝ $225.00Low
11/4/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$340.00 ➝ $330.00Low
11/4/2022CowenBoost Target$327.00 ➝ $350.00Low
11/4/2022Credit Suisse GroupLower TargetNeutral$230.00 ➝ $225.00N/A
11/4/2022CowenBoost Target$327.00 ➝ $350.00Low
11/4/2022Robert W. BairdLower Target$215.00 ➝ $210.00Low
10/11/2022ArgusLower Target$300.00 ➝ $250.00Low
10/4/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$220.00 ➝ $270.00Low
9/30/2022BarclaysBoost TargetUnderweight$130.00 ➝ $175.00Low
9/28/2022OTR GlobalDowngradePositiveLow
9/28/2022Evercore ISIUpgradeIn-Line ➝ Outperform$170.00 ➝ $250.00Low
8/24/2022Credit Suisse GroupInitiated CoverageNeutral$230.00Low
8/17/2022UBS GroupLower TargetNeutral$350.00 ➝ $245.00Low
8/15/2022Evercore ISILower Target$170.00N/A
8/15/2022CowenLower Target$327.00N/A
8/15/2022BarclaysLower Target$130.00N/A
8/15/2022Atlantic SecuritiesLower Target$190.00N/A
8/12/2022Morgan StanleyLower TargetEqual Weight$350.00 ➝ $240.00Low
8/12/2022Bank of AmericaLower Target$220.00 ➝ $200.00Low
8/12/2022Piper SandlerLower TargetOverweight$360.00 ➝ $320.00Low
8/12/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$450.00 ➝ $380.00Low
8/12/2022SVB LeerinkLower TargetMarket Perform$225.00 ➝ $220.00Low
8/12/2022Stifel NicolausLower TargetBuy$480.00 ➝ $300.00Low
8/12/2022CitigroupLower TargetNeutral$220.00 ➝ $200.00Low
8/12/2022Robert W. BairdLower Target$306.00 ➝ $215.00Low
7/19/2022CowenSet Target$412.00Low
7/13/2022BarclaysDowngradeEqual Weight ➝ Underweight$350.00 ➝ $150.00N/A
7/8/2022CitigroupLower TargetNeutral$325.00 ➝ $220.00N/A
5/15/2022Piper SandlerLower TargetNA$460.00 ➝ $360.00Low
5/6/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$555.00 ➝ $520.00High
5/6/2022CowenLower Target$506.00 ➝ $492.00High
5/6/2022CowenLower Target$506.00 ➝ $492.00High
5/6/2022CitigroupLower Target$400.00 ➝ $325.00High
3/29/2022OTR GlobalUpgradeMixed ➝ PositiveMedium
2/15/2022Piper SandlerBoost TargetOverweight$450.00 ➝ $460.00Medium
2/11/2022Robert W. BairdLower Target$437.00 ➝ $380.00High
2/11/2022SVB LeerinkLower TargetMarket Perform$430.00 ➝ $400.00High
1/18/2022Stifel NicolausUpgradeHold ➝ Buy$480.00High
1/11/2022BarclaysUpgradeUnderweight ➝ Equal Weight$432.72 ➝ $412.00High
1/11/2022SVB LeerinkBoost TargetMarket Perform$420.00 ➝ $430.00High
1/10/2022BarclaysLower TargetUnderweight$365.00 ➝ $350.00High
1/7/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$390.00High
1/6/2022CitigroupLower TargetNeutral ➝ Neutral$450.00 ➝ $400.00High
1/6/2022Morgan StanleyInitiated CoverageNeutral ➝ Equal Weight$425.00High
11/8/2021Robert W. BairdLower TargetNeutral$493.00 ➝ $437.00High
10/19/2021SVB LeerinkLower TargetMarket Perform$425.00 ➝ $420.00Low
8/22/2021Robert W. BairdReiterated RatingHoldMedium
8/19/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$425.00High
8/6/2021BarclaysBoost TargetUnderweight$355.00 ➝ $365.00Low
8/6/2021Piper SandlerBoost TargetOverweight$510.00 ➝ $560.00High
7/29/2021SVB LeerinkReiterated RatingBuyLow
7/13/2021BarclaysBoost TargetUnderweight$300.00 ➝ $355.00Low
4/28/2021Wells Fargo & CompanyBoost TargetUnderweight$330.00 ➝ $340.00High
4/6/2021Wells Fargo & CompanyBoost TargetUnderweight$300.00 ➝ $330.00Medium
3/31/2021Atlantic SecuritiesDowngradeOverweight ➝ Neutral$390.00High
3/2/2021BarclaysInitiated CoverageUnderweight$325.00High
2/16/2021BTIG ResearchBoost TargetBuy$410.00 ➝ $570.00Low
2/12/2021Piper SandlerBoost TargetOverweight$415.00 ➝ $510.00Low
2/12/2021CowenBoost TargetOutperform$385.00 ➝ $460.00Low
2/12/2021SVB LeerinkBoost TargetOutperform$360.00 ➝ $470.00Low
12/22/2020OTR GlobalUpgradePositiveMedium
12/22/2020Piper SandlerUpgradeNeutral ➝ Overweight$340.00 ➝ $415.00Medium
12/17/2020BTIG ResearchUpgradeNeutral ➝ Buy$410.00Medium
12/16/2020Smith Barney CitigroupBoost Target$330.00 ➝ $335.00Low
12/7/2020SVB LeerinkBoost TargetPositive ➝ Outperform$325.00 ➝ $360.00Low
12/1/2020ArgusLower Target$380.00 ➝ $355.00Low
10/30/2020SVB LeerinkBoost TargetOutperform$315.00 ➝ $325.00High
10/13/2020GuggenheimDowngradeBuy ➝ NeutralMedium
9/30/2020Atlantic SecuritiesInitiated CoverageOverweight$355.00 ➝ $355.00Medium
9/29/2020Wolfe ResearchDowngradeOutperform ➝ Peer PerformLow
9/22/2020Robert W. BairdLower TargetNeutral$335.00 ➝ $281.00Low
9/22/2020SVB LeerinkLower TargetOutperform$360.00 ➝ $315.00Low
9/22/2020Stifel NicolausDowngradeBuy ➝ Hold$380.00 ➝ $280.00Low
9/22/2020UBS GroupDowngradeBuy ➝ Neutral$390.00 ➝ $285.00Low
9/21/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$390.00 ➝ $280.00Low
9/21/2020GuggenheimUpgradeNeutral ➝ Buy$345.00High
9/11/2020ArgusReiterated RatingBuy ➝ Reduce$380.00 ➝ $380.00Low
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$400.00Low
8/7/2020SVB LeerinkLower TargetOutperform$370.00 ➝ $360.00High
8/7/2020Evercore ISIDowngradeIn-Line ➝ Underperform$310.00High
8/7/2020Piper SandlerDowngradeOverweight ➝ Neutral$356.00 ➝ $340.00High
7/7/2020GuggenheimDowngradeBuy ➝ NeutralLow
7/2/2020JPMorgan Chase & Co.Boost TargetOverweight$340.00 ➝ $390.00Low
5/21/2020ArgusBoost Target$340.00 ➝ $380.00Low
5/1/2020Piper SandlerLower TargetPositive ➝ Overweight$370.00 ➝ $356.00Low
5/1/2020Wells Fargo & CompanyBoost TargetUnderweight$245.00 ➝ $290.00Low
5/1/2020Stifel NicolausBoost TargetBuy$298.00 ➝ $325.00High
5/1/2020CowenBoost TargetOutperform$275.00 ➝ $320.00Medium
4/24/2020CitigroupDowngradeBuy ➝ Neutral$250.00 ➝ $320.00Low
4/21/2020Robert W. BairdDowngradeOutperform ➝ Neutral$310.00High
4/15/2020Robert W. BairdLower TargetOutperform ➝ Outperform$339.00 ➝ $310.00Medium
4/2/2020Stifel NicolausLower TargetBuy$345.00 ➝ $298.00Medium
3/30/2020Wells Fargo & CompanyLower TargetUnderweight$290.00 ➝ $245.00Medium
3/26/2020BarclaysLower TargetOverweight$390.00 ➝ $350.00High
3/20/2020CitigroupLower TargetBuy$350.00 ➝ $250.00Low
2/4/2020Credit Suisse GroupReiterated RatingBuy$340.00Low
1/30/2020Wells Fargo & CompanyLower TargetUnderweight$300.00 ➝ $290.00Low
1/30/2020CitigroupLower TargetBuy$385.00 ➝ $350.00High
1/9/2020Piper SandlerBoost TargetOverweight$341.00 ➝ $370.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageUnderweight$300.00Medium
1/6/2020CitigroupInitiated CoverageBuy$385.00Low
1/3/2020UBS GroupUpgradeNeutral ➝ Buy$355.00Medium
12/18/2019CowenReiterated RatingOutperform$320.00 ➝ $335.00Medium
11/14/2019Stifel NicolausInitiated CoverageBuy$345.00Medium
10/25/2019CowenSet TargetBuy$320.00Low
10/25/2019Wolfe ResearchSet TargetBuy$380.00N/A
10/25/2019Piper Sandler CompaniesLower TargetOverweight$348.00 ➝ $341.00High
10/25/2019GuggenheimInitiated CoverageBuy ➝ Buy$350.00 ➝ $350.00High
9/27/2019Piper Sandler CompaniesSet TargetBuy$348.00Medium
9/25/2019ArgusBoost TargetBuy$300.00 ➝ $340.00Medium
7/31/2019Credit Suisse GroupReiterated RatingBuy$340.00Medium
7/30/2019UBS GroupBoost TargetBuy$350.00 ➝ $355.00Low
7/30/2019Piper Sandler CompaniesLower TargetOverweight$382.00 ➝ $348.00Low
7/18/2019ArgusLower TargetBuy$340.00Low
7/12/2019CowenLower TargetOutperform$380.00 ➝ $320.00Low
7/12/2019Deutsche Bank AktiengesellschaftLower TargetHold$290.00 ➝ $280.00High
7/12/2019Bank of AmericaDowngradeBuy ➝ Underperform$310.00High
(Data available from 6/13/2019 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 35 positive mentions
  • 7 negative mentions
  • 11 very negative mentions
11/16/2023
  • 15 very positive mentions
  • 40 positive mentions
  • 15 negative mentions
  • 6 very negative mentions
12/16/2023
  • 23 very positive mentions
  • 65 positive mentions
  • 11 negative mentions
  • 14 very negative mentions
1/15/2024
  • 30 very positive mentions
  • 24 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
2/14/2024
  • 31 very positive mentions
  • 30 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
3/15/2024
  • 26 very positive mentions
  • 29 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
4/14/2024
  • 25 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/14/2024
  • 30 very positive mentions
  • 27 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
6/13/2024

Current Sentiment

  • 30 very positive mentions
  • 27 positive mentions
  • 7 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Illumina logo
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
Read More

Today's Range

Now: $108.51
Low: $108.46
High: $116.78

50 Day Range

MA: $115.64
Low: $101.05
High: $133.57

52 Week Range

Now: $108.51
Low: $89.00
High: $212.49

Volume

2,115,545 shs

Average Volume

1,851,706 shs

Market Capitalization

$17.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Illumina?

The following Wall Street sell-side analysts have issued research reports on Illumina in the last year: Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Citigroup Inc., Credit Suisse Group AG, Evercore ISI, Guggenheim, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., OTR Global, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Scotiabank, Stephens, Stifel Nicolaus, StockNews.com, TD Cowen, UBS Group AG, and Wolfe Research.
View the latest analyst ratings for ILMN.

What is the current price target for Illumina?

21 Wall Street analysts have set twelve-month price targets for Illumina in the last year. Their average twelve-month price target is $158.14, suggesting a possible upside of 45.7%. Royal Bank of Canada has the highest price target set, predicting ILMN will reach $253.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $100.00 for Illumina in the next year.
View the latest price targets for ILMN.

What is the current consensus analyst rating for Illumina?

Illumina currently has 2 sell ratings, 11 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ILMN, but not buy more shares or sell existing shares.
View the latest ratings for ILMN.

What other companies compete with Illumina?

How do I contact Illumina's investor relations team?

Illumina's physical mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company's listed phone number is (858) 202-4500 and its investor relations email address is [email protected]. The official website for Illumina is www.illumina.com. Learn More about contacing Illumina investor relations.